Geode Capital Management’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,237,550
| Closed | -$41.4M | – | 4552 |
|
|
2026
Q1 | $41.4M | Buy |
1,237,550
+74,212
| +6% | +$2.91M | ﹤0.01% | 1599 |
|
|
2025
Q4 | $53.9M | Buy |
1,163,338
+78,386
| +7% | +$4.3M | ﹤0.01% | 1432 |
|
|
2025
Q3 | $73.4M | Buy |
1,084,952
+182,556
| +20% | +$13.5M | ﹤0.01% | 1251 |
|
|
2025
Q2 | $75.6M | Buy |
902,396
+286,660
| +47% | +$21.5M | 0.01% | 1193 |
|
|
2025
Q1 | $44M | Buy |
615,736
+16,617
| +3% | +$809K | ﹤0.01% | 1444 |
|
|
2024
Q4 | $26.9M | Buy |
599,119
+58,823
| +11% | +$3.05M | ﹤0.01% | 1797 |
|
|
2024
Q3 | $27.3M | Buy |
540,296
+51,189
| +10% | +$2.45M | ﹤0.01% | 1815 |
|
|
2024
Q2 | $20M | Buy |
489,107
+322,086
| +193% | +$13.6M | ﹤0.01% | 1929 |
|
|
2024
Q1 | $7.15M | Buy |
167,021
+4,177
| +3% | +$189K | ﹤0.01% | 2521 |
|
|
2023
Q4 | $6.56M | Buy |
162,844
+110,291
| +210% | +$3.14M | ﹤0.01% | 2565 |
|
|
2023
Q3 | $1.55M | Sell |
52,553
-2,095
| -4% | -$12.7K | ﹤0.01% | 3164 |
|
|
2023
Q2 | $234K | Buy |
54,648
+22,092
| +68% | +$95K | ﹤0.01% | 3976 |
|
|
2023
Q1 | $69.7K | Hold |
32,556
| – | – | ﹤0.01% | 4442 |
|
|
2022
Q4 | $64K | Hold |
32,556
| – | – | ﹤0.01% | 4526 |
|
|
2022
Q3 | $54K | Sell |
32,556
-4
| -0% | -$10 | ﹤0.01% | 4752 |
|
|
2022
Q2 | $90K | Buy |
32,560
+3,876
| +14% | +$10.7K | ﹤0.01% | 4631 |
|
|
2022
Q1 | $95K | Hold |
28,684
| – | – | ﹤0.01% | 4679 |
|
|
2021
Q4 | $176K | Hold |
28,684
| – | – | ﹤0.01% | 4535 |
|
|
2021
Q3 | $397K | Buy |
28,684
+1,213
| +4% | +$16.9K | ﹤0.01% | 4143 |
|
|
2021
Q2 | $469K | Sell |
27,471
-27,712
| -50% | -$468K | ﹤0.01% | 3974 |
|
|
2021
Q1 | $1.04M | Buy |
55,183
+7,216
| +15% | +$233K | ﹤0.01% | 3542 |
|
|
2020
Q4 | $1.39M | Buy |
47,967
+10,166
| +27% | +$293K | ﹤0.01% | 3256 |
|
|
2020
Q3 | $1.42M | Buy |
37,801
+13,276
| +54% | +$388K | ﹤0.01% | 3065 |
|
|
2020
Q2 | $816K | Buy |
24,525
+15,181
| +162% | +$658K | ﹤0.01% | 3206 |
|
|
2020
Q1 | $333K | Buy |
9,344
+5,551
| +146% | +$236K | ﹤0.01% | 3390 |
|
|
2019
Q4 | $167K | Buy |
3,793
+1,453
| +62% | +$37.2K | ﹤0.01% | 3859 |
|
|
2019
Q3 | $52K | Hold |
2,340
| – | – | ﹤0.01% | 4058 |
|
|
2019
Q2 | $98K | Buy |
2,340
+404
| +21% | +$14K | ﹤0.01% | 3967 |
|
|
2019
Q1 | $59K | Hold |
1,936
| – | – | ﹤0.01% | 3988 |
|
|
2018
Q4 | $49K | Hold |
1,936
| – | – | ﹤0.01% | 3992 |
|
|
2018
Q3 | $62K | Buy |
+1,936
| New | +$70.3K | ﹤0.01% | 4004 |
|
Geode Capital Management's SLNO Position: Q2 2026 in Review
Geode Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 1,237,550 shares — an estimated $41.4M sold.
Geode Capital Management first reported a position in SLNO in Q3 2018 and held it in 31 quarters. The position peaked at $75.6M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Geode Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Geode Capital Management sold 1,237,550 Soleno Therapeutics shares in Q2 2026, an estimated $41.4M.
- Geode Capital Management first reported a position in Soleno Therapeutics in Q3 2018 and held it in 31 quarters.
- Geode Capital Management's Soleno Therapeutics position peaked at $75.6M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.